Night_Owl_Biotech
Posted - 12 hours ago
Our records indicate 7 commercial-stage biopharmas beat analyst consensus revenue estimates by more than 15% in both Q1 & Q2 2024. Attached you will note Q1, Q2 & Q3 revenue data & graphs of their share prices year to date. Q3 estimates are per Seeking Alpha as of 10/28/24. So far, $DCTH is the only one of the 7 commercial-stage bios to beat analyst estimates by more than 15% for all 3 quarters year-to-date. DCTH has not released official Q3 2024 financials yet but did disclose preliminary Q3 2024 revenues early. Of course others may or may not follow including $TARS $BPMC $TGTX. $ESPR revenues include significant non-product revenues (collaboration). Some graphs (SWTX) speak for themselves. We'd highlight SWTX if we did not post about them so much already. This is not investment advice. All bios noted on the attachment have only 1 FDA approved therapy/API (excl BPMC) & therefore could go bankrupt if their product was taken off the market.
kmx_swing
Posted - 15 hours ago
$DCTH chart is pushing it to $9.50 before it goes over $12...chart is more important than company and its achievements...funny market...😊
titan888
Posted - 4 days ago
$DCTH CEO adding 17K shares with warrants now has 319K shares
Playthegame06
Posted - 5 days ago
$DCTH Looks like Gerard was part of the Tranche B Warrants. He got 16,666 shares @ $6.00.
Tell me if that’s not CONFIDENCE in the CEO.
TradeWinner
Posted - 5 days ago
$DCTH Feels like when and not if the 52 week high is broken in the near future. The bigger question is where will we be in 12 months or 24 months. Etc.
Playthegame06
Posted - 6 days ago
$DCTH I'm not a doctor but there could be similarities between the liver and pancreas. WIKI - The liver and pancreas share a common embryological origin and have similar exocrine organization. They also both have parenchymal cells that secrete substances into the duodenum
Playthegame06
Posted - 6 days ago
$DCTH Expect another bump higher when the $25M is received.
Jaymuss
Posted - 6 days ago
$DCTH Is there a possibility DCTH's liver treatment could be done on the pancreas ?
brunoq14
Posted - 1 week ago
$DCTH When we get to the actual earnings date, there will be a much greater emphasis on the reduction of the quarterly loss (cut in half), and the amount by which analysts' revenue estimates were surpassed. Also possible that we will add additional REMS sites by then.
Thestocktraderhubzee
Posted - 1 week ago
WATCHLIST OCT 21 2024..
$AURA Scotiabank Maintains Sector Outperform on Aura Biosciences, Raises Price Target to $23
$KEY Barclays Maintains Equal-Weight on KeyCorp, Raises Price Target to $19
$STEM Barclays Maintains Equal-Weight on Stem, Lowers Price Target to $1
$GMRE Berenberg Initiates Coverage On Global Medical REIT with Buy Rating, Announces Price Target of $11.75
$DCTH Canaccord Genuity Maintains Buy on Delcath Systems, Maintains $21 Price Target
Playthegame06
Posted - 1 week ago
$DCTH Do you “really” want to see DCTH’s numbers???
Playthegame06
Posted - 1 week ago
$DCTH Great Close!! I love AVGING UP!!!
titan888
Posted - 1 week ago
$DCTH wow
mar99
Posted - 1 week ago
$DCTH Quite an impressive rebound week for DCTH. Looking like a new closing high for the year today if it holds up. I believe previous high close was 11.00.
TradeWinner
Posted - 1 week ago
$DCTH lets go. Nice move over the last two days. Feel a little sorry for the ones that had sold out prior. Hold those shares tight.
Playthegame06
Posted - 1 week ago
$DCTH If DCTH European Revenues reached $1.2M that’s an awful lot of procedures like 60 in the Qtr. if they came get the ASP up to $75k that’s a nice Revenue stream.
brunoq14
Posted - 1 week ago
$DCTH Delcath's projected expansion into other areas of oncologic surgery, such as HCC and colorectal, should be greatly facilitated by the use of the device in such surgeries over the last ten years in Europe, where it was approved as a device for unrestricted use, as opposed to the US where it was approved as a drug for a specific type of cancer. That successful real world use should give the expansion a valuable head start.
Playthegame06
Posted - 1 week ago
$DCTH HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Delcath Systems (NASDAQ:DCTH) with a Buy and maintains $22 price target.
Playthegame06
Posted - 1 week ago
$DCTH HC Wainwright & Co. Reiterates Buy on DCTH, Maintains $22 Price Target
LudwigVanBeethoven
Posted - 1 week ago
$DCTH the 8 bounce worked well.
Ai_Quantum_Bullnutz
Posted - 1 week ago
$DCTH lmao this ticker has always been a play toy pump
I remember this one back in 2017 or 2018
TylerDrdn
Posted - 1 week ago
$DCTH median price to sales ration in drugs (pharmaceuticals) industry is 4.51, and that is with crazy market multiples. Long term average is much less....
kmx_swing
Posted - 1 week ago
$DCTH geometrical sequence of sites involved only to start...
TylerDrdn
Posted - 1 week ago
$DCTH About 4.4 million new shares will be created at $6, with $4 profit immediately available. Plus there is still a danger of management going for a large offering to fund "other indications", if they can't find a suitable partner. Other then that, things are great....
brunoq14
Posted - 1 week ago
$DCTH If we do $11.2M with 12 REMS sites, how much does 20-35 imply?
brunoq14
Posted - 1 week ago
$DCTH Probably will also be a big earnings improvement as well, close to ($0.20) rather than ($0.40).
brunoq14
Posted - 1 week ago
$DCTH Once again we hit the high estimate on Yahoo Finance. The average estimate was $9.45M. Another big revenue beat.
annee33
Posted - 1 week ago
$DCTH beautiful chart, but still under the radar
titan888
Posted - 1 week ago
$DCTH very impressive growth, soon to be profitable